Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), which focuses on central nervous disorders conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia.
Needham对Axsome Therapeutics Inc (纳斯达克:AXSM)进行了覆盖，其专注于中枢神经系统疾病，包括抑郁症，阿尔茨海默病的烦躁，偏头痛，嗜睡症和纤维肌痛。
Needham writes that Axsome Therapeutics' diversified CNS portfolio will help grow the risk-adjusted topline by 8-10x in five years.
Needham认为Axsome Therapeutics的多元化中枢神经系统产品组合将帮助在五年内将风险调整后的净收入提高8-10倍。
The analyst anticipates an upside for Axsome Therapeutics on its two marketed drugs, Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness.
分析师预计Axsome Therapeutics的两种上市药品Auvelity和Sunosi有上升空间，Auvelity用于治疗重度抑郁症，Sunosi用于缓解白天过度嗜睡。
Related: Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says.
相关：Axsome研发的抑郁症药物商业成功，线管潜力被低估，分析师表示。
Physicians report a positive experience with Auvelity due to its novel mechanism of action, rapid onset, and efficacy. However, they note that payer coverage could be better. Physicians were generally positive about increasing their use of Auvelity, but Needham does not anticipate better-than-expected growth for the drug.
医生们使用Auvelity的体验良好，这归因于它的新颖作用机制，快速起效和疗效。然而，他们指出，付款人覆盖范围可能会更好。医生们普遍持积极态度，愿意增加使用Auvelity的频率，但是Needham不预计该药物的增长会超出预期。
Needham initiated with a Buy rating and a price target of $130.
Needham给予买入评级，目标价为130美元。
The analyst says the company's most significant pipeline asset, AXS-05 in Alzheimer's Disease agitation, is already de-risked based on two positive Phase 3 trial data, and the ADVANCE-2 Ph 3 readout this year will support a filing.
分析师表示，公司最重要的管线资产AXS-05在阿尔茨海默病烦躁方面已经通过两项积极的第3期试验结果降低了风险，ADVANCE-2 Phase 3 的结果将支持提交。
Needham estimates 2028 US sales of ~$550 million (+11% vs. cons), growing to ~$1 billion in 2030
Needham预计2028年美国销售额约为55000000美元（+11％ vs.共识），到2030年将增长到10亿美元。
Currently, Axsome receives no value for its remaining pipeline, but several of these products are in the late stages.
目前，Axsome的其余产品线没有价值，但其中几个产品已处于后期阶段。
Needham anticipates they will contribute to topline growth soon.
Needham预计它们将很快为净收入增长贡献。
Axsome has three late-stage assets: AXS-07 for migraine, AXS-14 for fibromyalgia—2Q24 filing, and AXS-12 for narcolepsy filing post-second half data safety data, which can collectively drive ~$1 billion in sales by 2030 with a 60-65% probability of success.
Axsome拥有三个后期资产：治疗偏头痛的AXS-07，治疗纤维肌痛的AXS-14-2Q24申请，以及AXS-12治疗嗜睡症，根据第二半年数据安全性数据提交审核。这些产品的共同推动力有望在2030年实现10亿美元的销售额，成功概率为60-65％。
Price Action: AXSM stock is up 1.21% at $85.88 at the last check on Monday.
股价异动：AXSm 股票在上周一最新股价为85.88美元，上涨1.21%。
- Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials.
- cassava sciences通过一项关键性的第3期试验推进阿尔茨海默病药物。
